A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

计划入组 420 人 · 首次发布于 2021 年 3 月 23 日

Menin-Inhibitor Targeted Maintenance in AML

计划入组 146 人 · 首次发布于 2026 年 5 月 1 日

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

计划入组 40 人 · 首次发布于 2024 年 1 月 29 日

Icovamenib

Ziftomenib(Komzifti)

C₃₃H₄₂F₃N₉O₂S₂

xenin-25

Biomea Fusion

United States

Kura Oncology

United States

University Of Benin

Nigeria

Revumenib Shows Breakthrough Results in Advanced Acute Myeloid Leukemia Trial

FDA Approves Syndax's Revuforj (axatilimab) as First Menin Inhibitor for Relapsed/Refractory AML

Syndax's Revumenib Meets Primary Endpoint in AML Trial Despite Stock Drop